For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

We’re hoping to see more early-stage funding in 2026 to help newer companies get off the ground. The public market, especially IPOs, has been a bit slow, with only 11 companies going public in 2025, ...

From Adelaide to San Francisco, the biotechnology landscape is shifting – and, in some cases, straining under the weight of ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Biotechnology is no longer distant science fiction; it’s already a growing force in both national security and local economies. It affects everything from how much you pay at the pharmacy to whether ...

In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding the state’s life science and biotechnology research industry. After nearly ...

What if our homes were alive? I don’t mean smart homes with the disembodied voice of Alexa deciding the setting for your living room spotlights. I mean actually alive – growing, living, breathing and ...

Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company ...

Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously ...